[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) CEO/Director Form 4 shows routine equity activity. On 11/17/2025, 40,390 Class A shares were withheld at $4.14 to cover tax obligations from net-settled restricted stock units, leaving 913,839 Class A shares directly owned. On 11/19/2025, the insider converted 40,000 Class B shares into Class A at $0 and sold 40,000 Class A shares at $4.16 under a Rule 10b5-1 trading plan adopted on May 12, 2025, maintaining direct ownership at 913,839 Class A shares.

The insider also reports derivative holdings, including Class B shares convertible into Class A with no expiration date and multiple stock options with exercise prices ranging from $2.48 to $11.40 and expirations extending to 2035. Some Class B holdings are reported indirectly through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gibson Christopher

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/17/2025		F(1)		40,390	D	$4.14	913,839	D
Class A Common Stock	11/19/2025		C(2)(3)		40,000	A	$0	953,839	D
Class A Common Stock	11/19/2025		S(2)		40,000	D	$4.16	913,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B Common Stock	$0(3)	11/19/2025		C(2)(3)			40,000	(3)	(3)	Class A Common Stock	40,000	$0	4,823,334	D
Class B Common Stock	$0							(3)	(3)	Class A Common Stock	0		386,000	I	by LAHWRAN-3 LLC(4)
Class B Common Stock	$0							(3)	(3)	Class A Common Stock	0		388,000	I	by LAHWRAN-4 LLC(5)
Class B Common Stock	$0							(3)	(3)	Class A Common Stock	0		50,000	I	by Gibson Family Trust(6)
Stock Option (Right to Buy)	$10.09							(7)	02/09/2034	Class A Common Stock	0		666,898	D
Stock Option (Right to Buy)	$7.25							(8)	02/03/2035	Class A Common Stock	0		1,050,567	D
Stock Option (Right to Buy)	$8.55							(9)	02/01/2033	Class A Common Stock	0		813,600	D
Stock Option (Right to Buy)	$11.4							(10)	02/04/2032	Class A Common Stock	0		399,002	D
Stock Option (Right to Buy)	$11.4							02/04/2022	02/04/2032	Class A Common Stock	0		5,436	D
Stock Option (Right to Buy)	$2.48							(11)	12/30/2030	Class A Common Stock	0		282,500	D

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.

3. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

4. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.

5. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.

6. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.

7. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

9. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

10. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

11. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did the RXRX CEO report on this Form 4?

The CEO of Recursion Pharmaceuticals (RXRX) reported three main transactions: 40,390 Class A shares withheld on 11/17/2025 to cover taxes on restricted stock units, the conversion of 40,000 Class B shares into Class A on 11/19/2025 at $0, and the sale of 40,000 Class A shares on 11/19/2025 at $4.16.

How many RXRX Class A shares does the CEO own after these transactions?

After the reported transactions, the CEO directly owns 913,839 shares of Class A Common Stock of Recursion Pharmaceuticals.

Was the RXRX CEO stock sale made under a Rule 10b5-1 trading plan?

Yes. The conversion and sale of 40,000 Class A shares on 11/19/2025 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.

Why were 40,390 RXRX shares withheld on 11/17/2025?

The 40,390 Class A shares were withheld by Recursion Pharmaceuticals to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units.

What is the relationship between RXRX Class B and Class A Common Stock for this insider?

Each reported share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

What indirect RXRX holdings does the CEO report?

The CEO reports indirect holdings of Class B Common Stock convertible into Class A through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, where the CEO is a member, manager, or trustee.

What stock options in RXRX does the CEO hold according to this Form 4?

The CEO reports several stock options (rights to buy Class A Common Stock) with exercise prices including $10.09, $7.25, $8.55, $11.40, and $2.48, with expirations between 02/04/2032 and 02/03/2035, and vesting monthly under the schedules described.